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ABSTRACT
BACKGROUND: Among women with unexplained infertility, 28% to 55% of
patients with galactorrhea are normoprolactinemic. Bromocriptine, a common treat-
ment for infertile women with hyperprolactinemia, has been used in the treatment of
unexplained subfertility in women with galactorrhea and normal prolactin; however,
its effectiveness and safety profile have never been determined.
OBJECTIVE: The aim of this study was to determine the relative effectiveness
and safety profile of bromocriptine monotherapy or as an adjunct to clomiphene cit-
rate in women with galactorrhea and normal prolactin levels.
METHODS: We conducted a search of the Cochrane Subferriliry Review Group
specialized register of controlled trials (March 2010), CENTRAL (The Cochrane
Library, Issue 3, 2010), MEDLINE (1950-March 2010), EMBASE 0980-March
2010), and the China Biological Medicine Database (inception to March 2010) for
relevant randomized controlled trials (RCTs) using the following terms: controlled,
randomized, blinded, clinical trials,humans, galactorrhea, prolactin, bromocriptine, mfertility,
and subfertility. Additionally, reference lim of identified articles were searched for
relevant articles.
RESULTS: Of the 8 studies identified, 5 were excluded after full-text review
for the following reasons: lack of a placebo group (2); difference in cointerventions (1);
difference in end points (1); and systematic review (1). Therefore, 3 RCTs were in-
cluded in this review. Bromocriptine administered in combination with clomiphene
was found to be associated with a higher accumulative pregnancy rate compared
with clomiphene monotherapy (fixed odds ratio [OR}, 5.33; 95% Cl, 2.62-10.88),
and a lower miscarriage rate (fixed OR, 0.20; 95% Cl, 0.05-0.76). Only 1 trial re-
ported live birth as an outcome, and multiple pregnancy rates were poorly reported.
Patient-reported adverse effects were mentioned in the studies, but reports were often
incomplete.
CONCLUSIONS: This review suggests the effectiveness of bromocriptine with
clomiphene for infertility in women with galactorrhea and normal prolactin levels.
Further RCTs of adequate power and of high methodologic quality are required
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to confirm these findings. (Curr Ther Res Clin Exp. 2010;71:199-210) © 2010 Ex-
cerpta Medica Inc.
KEY WORDS: bromocriptine, galactorrhea, infertility, prolactin, randomized
controlled trial, meta-analysis.
INTRODUCTION
Infertility is defined as 1 year of unprotected coitus without conception. 1 This is one
of the most common reasons women are referred to gynecologic clinical centers. There
are -2.5 million infertile couples in the United States; that is, 10% to 15% of the
world's infertile population.' Approximately 40% of infertility is due to female factors
(eg, salpingemphraxis, uterine malformation) and anovulation constitutes -40% ofall
female infertility.- Causes of anovulation are divided into 3 categories by the World
Health Organization (WHO).3 Hypothalamic pituitary failure or hypogonadotrophic
hypogonadism (category 1) accounts for -10% of ovulatory disorders. Hypothalamic
pituitary or eugonadotropic dysfunction (category 2) accounts for -85% of ovulatory
disorders. The remaining 4% to 5% of ovulatory disorders are due to ovarian failure or
hypergonadotropic hypogonadism (category 3). Category 2 consists predominantly of
women with polycystic ovary syndrome (PCOS) but also may include hyperprolactin-
emia and women with unexplained anovulation. Here we noticed unexplained subfertili-
ty caused by unexplained anovulation of normal prolactin with galactorrhea.
Galactorrhea is a discharge of milk or a milk-like secretion from the breast in the
absence of parturition, or beyond 6 months postpartum, in a nonbreastfeeding wornan.f
The pathologic causes of galactorrhea include pituitary tumor, hypothalamic and pitu-
itary stalk lesions, neurogenic stimulation, thyroid disorders, and chronic renal failure.
Prolactin is secreted by the anterior pituitary and is a peptide protein hormone that
plays an important role in reproduction. Normal prolactin levels are <20 ng/mL and
abnormal levels have been found to induce galactorrhea and other adverse effects."
Galactorrhea with hyperprolactinemia can lead to luteal phase dysfunction and, as a
result, infertility. The main mechanism of action in hyperprolactinemia is the inhibi-
tion of pulsatile gonadotropin-releasing hormone (GnRH) secretion, which results in a
hypoestrogenic state; galactorrhea is a common result in these cases.1 Galactorrhea pres-
ent in a normal level of prolactinemia associated with ovulatory dysfunction may have
similar abnormal patterns of pulsatile luteinizing hormone secretion.f
The decision to treat patients with galactorrhea is based on the serum prolactin
level, the severity of galactorrhea, and the patient's fertility desires.f The United
Kingdom National Institute for Clinical Excellence guidelines state that first-line
treatment for WHO-defined group 2 anovulation should be clomiphene (or tarnoxi-
fen) for up to 12 rnonths.t Clomiphene with or without adjunct medication is, at
present, the first-line treatment for anovulatory women. Clomiphene is an antiestrogen
and competes for receptor binding sites with endogenous estrogens. By blocking re-
ceptors in the hypothalamus and pituitary, clomiphene interferes with the feedback
mechanism of endogenous estrogen on the pituitary and hypothalamus, resulting
in increased follicle-stimulating hormone and luteinizing hormone secretion. Ovarian
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hyperstimulation syndrome has been reported rarely following clomiphene use." How-
ever, clomiphene resistance (failure to ovulate after taking clomiphene) is common
and occurs in -15% to 40% of women with rcos- Unexplained anovulation in
patients who have galactorrhea with normal prolactin level often remains untreated."
Alternative and adjunctive treatments have been sought due to the high incidence of
this kind. Bromocriptine, which is used for ovulation induction, has been found to be
effective in hyperprolactinemic wornen.!"
Bromocriptine is a dopamine agonist used to lower prolactin levels, increase GnRH
secretion, and induce ovulation." For this reason, bromocriptine has been studied as
an adjunctive treatment to clomiphene for ovulation induction in anovulatory women.
It has been reported to induce a return to cyclical ovarian activity in norrnopro-
lactinemic women with PCOS.II It has been suggested that the presence of normo-
prolactinemic galactorrhea in patients with ovulatory dysfunction may represent a
covert disorder of prolactin-related physiologic factors, and may also respond well to
bromocriptine.l/ The effect of treatment with bromocriptine in women with primary
or secondary infertility and normal prolactin serum level with galactorrhea has been
investigated. An implicit treatment mechanism is currently not very clear"; the use of
bromocriptine for galactorrhea or luteal phase dysfunction can inhibit galactorrhea
and induce ovularion.l '
Whether bromocriptine has beneficial effects in the ovulatory dysfunction associ-
ated with galactorrhea even with normal prolactin levels is not known. We reviewed
the available literature in an attempt to establish the effectiveness and safety profile
of bromocriptine monotherapy or in combination with clomiphene in ovulation in-
duction on this kind of patient.
Symptoms of patients with ovulatory dysfunction include galactorrhea, irregular
menstruation, and infertility.l" Bromocriptine may be worthwhile for women with
unexplained subfertility who also have expressible galacrorrhea.l?
METHODS
SELECTION CRITERIA
We conducted a search of the Cochrane Subfertility Review Group specialized reg-
ister of controlled trials (March 2010), CENTRAL (The Cochrane Library, Issue 3,
2010), MEDLINE (1950-March 2010), EMBASE 0980-March 2010), and the
China Biological Medicine Database (inception to March 2010) for relevant random-
ized controlled trials (RCTs) using the following exploded (exp) medical subject head-
ing terms: exp (controlled OR randomized, OR blinded AND clinical trials) AND
humans AND (galactorrhea and prolactin and bromocriptine) AND (infertility or
subfertility). The search strategy was developed by database specialty personnel not
associated with the study. Reference lists from pertinent reviews and retrieved articles
were also checked to identify additional studies. In addition, we attempted to find
data from poster presentations and by consulting several experts in the field.
In the systematic review, the following inclusion criteria were established: each
trial should (1) be a prospective clinical RCT; (2) report on bromocriptine monothera-
py or with adjuncts; (3) enroll women with unexplained subfertility and galactorrhea
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with normal prolactin levels; (4) be a randomized comparison ofbromocriptine versus
placebo or blank control, regardless of the initial time of treatment, treatment dura-
tion, dose and administration route of the drug; and (5) report concomitant interven-
tions (including treating complications) if administered equally to all intervention
groups. Two reviewers (T.X. and YW.), who worked independently, used these criteria
to review each article identified.
A study was excluded if: (1) it was quasi randomized or nonrandomized; (2) patients
with hyperprolactinemic infertility, breast disease, or conditions not suitable for bro-
mocriptine were excluded; (3) the patients used rnetformin or other insulin-sensitizing
agents; (4) there were differences in the concomitant interventions between srudy groups;
(5) the report was repetitive (if> 1 version of the same study was retrieved, only the
most recent was used).
DATA EXTRACTION
The two reviewers applied the eligibility criteria and assessed trial quality indepen-
dently. Inconsistencies between reviewers' data were resolved through discussion until
a consensus was reached. Each RCT was scored for quality to assess validity using the
]adad Quality Score system.l" If the score of a study was> 3, it was considered a high-
quality study. 17 The extracted data included characteristics of the trial, patients, inter-
ventions, and outcomes. The primary outcome was pregnancy rate; secondary out-
comes were ovulation, miscarriage, and patient-reported adverse events (AEs).
QUALITY ASSESSMENT
Trials were screened and analyzed for the following quality criteria: (1) method and
timing of randomization: randomized (eg, by computer, random number tables, or
drawing lots), quasirandomized (eg, hospital number, date of birth), unclear (eg, ran-
domization claimed but not further described); (2) concealment of allocation: adequate
(eg, third party, sealed opaque envelopes), inadequate (eg, open list of allocation
codes), unclear (eg, not stated, or 'envelope method' stated without further descrip-
tion); (3) study blinding; (4) whether an intent-to-treat analysis was performed; and
(5) whether a power calculation was conducted a priori. Trials rated as quasi random-
ized were excluded from this review.
STATISTICAL ANALYSIS
Meta-analysis was performed according to recommendations from The Cochrane
Collaboration18 and the quality of reporting of meta-analyses guidelines. 19 The effect
measures estimated were odds ratio (OR) for dichotomous data and weighted mean
difference for continuous data, both reported with 95% CIs. The OR represented the
odds of an AE occurring in the bromocriptine group versus the comparator. An OR
of < 1 favored the latter group. The point estimate of the OR was considered statisti-
cally significant at P < 0.05 if the 95% CI did not include the value 1.
Studies that contained a zero in 1 cell for the number of events of interest in 1 of
the 2 groups resulted in problems with the computation of ratio measurement; there-
fore, on the recommendation of a statistician, a value of O. 5 was added in both groups
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for those studies. Heterogeneity between the results of different trials was examined
by inspecting the scatter of data points on a graph and the overlap in their CIs and,
more formally, by a X2 test. P < 0.1 was considered statistically significant in regard
to heterogeneity. Fixed-effects models were used throughout, unless statistical hetero-
geneity was significant, in which case a random-effects model was used. Analysis was
performed using the statistical software Intercooled Stata version 8.2 (Stata Corp, College
Station, Texas) and Review Manager version 4.2 (The Cochrane Collaboration, Oxford,
United Kingdom).
If a clinically important difference in drug regimen (outside of normal clinical
practice) had occurred between trials an attempt to form dose subgroups for analysis
would have been made.
RESULTS
The search strategy initially generated 8 studies (Figure 1); no further studies were
found beyond the database search. After full-text review, 5 trials were excluded: 2 did
nor consider a placebo group9,13; 1 had a difference in cointerventions between treat-
ment groups/"; 1 was a systematic reviewl '; and 1 had differing end poinrs.?! There-
fore, 3 RCTs were identified that satisfied all of the inclusion criteria for this review
(Table I and Table II).
Potentially appropriate
studies identified
(n = 5)
Additional studies identified
from CBM and reference
list of pertinent reviews
Assessed trials
(n = 8)
Studies excluded (n = 5)
Placebo group lacking (2)
Different cointerventions (1)
Different end points (1)
Systematic review (1)
Randomized controlled trials
included in the meta-analysis
(n = 3)
Figure 1. Identification of eligible randomized controlled trials. CBM = China Biological
Medicine Database.
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Table II. Jadad Quality Score16 of randomized controlled trials included in the meta-
analysis.
Reference
Akhlaghi and
Harnedi-?
Anzhen and
Liang23
Haixia24
Year of
Publication
2004
2006
2002
Randomization
Centralized randomization
schedule
Randomization
mentioned, but method
not specified
Randomization
mentioned, but method
not specified
Withdrawals/
Jadad Blinding
Only mentioned/
double-blind
No withdrawals/
double-blind
No withdrawals/
blinding unclear
Scores
5
4
3
INCLUDED STUDIES
No RCTs were found for the following interventions: bromocriprine monotherapy
versus placebo and bromocriptine monotherapy versus clomiphene monotherapy.
Three RCTs compared bromocriptine plus clomiphene versus bromocriptine mono-
therapy (Table I).
The study by Akhlagi and Hamedi22was an RCT of 44 women with galactorrhea,
normal serum prolactin and dehydroepiandrosterone sulfate levels, normal coned-down
view (in the radiographic evaluation of sella turcica), normal hysterosalpingogram,
normal spermiogram, and a failure to ovulate. Patients were administered a high dose
of clomiphene citrate (100 mg/d from the 5th through the 9th days of the menstrual
cycle) or bromocriptine (2.5 mg BID for 3 months). Regular menstrual cycles re-
sumed in 68.2% of the clomiphene group and 50.0% of the second group. The preg-
nancy rates were 40.0% and 22.7%, respectively. No AEs were reported.
Anzhen and Liang23conducted an RCT in 53 patients with galactorrhea, normal
serum prolactin, normal hysterosalpingogram, and normal spermiogram. Patients
received clomiphene (50 mg/d from the 5th through the 9th days of the menstrual
cycle) or bromocriptine (1.25 mg/d for 3 months). Pregnancy rates were 74.1% and
34.6%, respectively. No AEs were reported.
The study by Haixia24 was an RCT in 57 patients with galactorrhea and normal
serum prolactin. Depending on other etiologic factors, patients received clomiphene (50-
100 mg/d from the 5th through the 9th days of the menstrual cycle) and/or brornocriptine
(2.5-5 mg/d for 3 months). Pregnancy rates were 85.2% and 33.3%, respectively.
OUTCOMES
All 3 included trials reported pregnancy rate; 2 reported miscarriage rate.23,24 Live
birth was reported in 1 triaP4 Patient-reported AEs were mentioned in studies but
reports were often incomplete.
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Primary Outcome
Pregnancy rate analysis suggested a large and consistent benefit of bromocriptine
plus clomiphene (154 patients; fixed OR = 5.33; 95% CI, 2.62-10.88) (Figure 2).
Secondary Outcomes
Miscarriage rate analysis suggested lower incidence in the bromocriptine plus clo-
miphene group (62 patients; fixed OR = 0.20; 95% CI, 0.05-0.76) (Figure 3). Ovu-
lation rates were not reported. Patient-reported AEs were so poorly reported in the
trials that we were unable to analyze them.
PUBLICATION BIAS
Publication bias was assessed for all pooled ORs with 95% CIs using the Begg
test. 25 The results presented the treatment effects estimated from individual studies
plotted on the horizontal axis (OR) against the SE of the estimate shown on the verti-
cal axis (SE [log OR}).26 All of the studies lay within the 95% CI and were uniformly
distributed around the vertical axis, suggesting a low likelihood of publication bias.
DISCUSSION
This review shows some evidence supporting the effectiveness of the current first-
line treatment in this kind of patient, clomiphene citrate in combination with
bromocriptine.
In infertile patients with galactorrhea and normal prolactin levels, application of
low-dose bromocriptine for ovulation-induction treatment may improve pregnancy
rates and lower miscarriage rates. However, the published evidence is limited. This
review included only 3 trials with a total of 154 participants. The inclusion and exclu-
sion criteria were dissimilar, there was discordance among the heterogeneity of the
study populations, and differences in experimental design.
Most previous studies focused on prolactin serum levels rather than galactorrhea.
It was found that infertile patients with galactorrhea and normal prolactin levels
had a significant response to bromocriptine treatment. This suggests that galactor-
rhea should be assessed by obstetricians and gynecologists in infertile patients. And,
in cases positive for galactorrhea, treatment with bromocriptine should be initiated
and followed up for 26 months before any other evaluations and treatments.? Clo-
miphene is now widely accepted as an effective treatment bur further trials on bro-
moeriptine alone or in combination with clomiphene citrate should be conducted.
LIMITATIONS
All of the trials included in this review had methodologic flaws, which weakens the
results found. More rigorous RCTs are required for all the interventions. Live birth
rate is the gold standard in primary outcome for RCTs of this nature, and only 1 of
the trials reported this and follow-up to delivery was not complete.
RCTs of the treatments, such as bromocriptine monotherapy or as an adjunct, for
unexplained subfertility in women with galactorrhea but normal prolactin levels that
are adequately powered and of high methodologic quality are needed.
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CONCLUSIONS
Bromocriptine taken concomitantly with clomiphene might be effective in increasing
accumulative pregnancy rates and lowering miscarriage rates of infertility in women
with galactorrhea and normal prolactin levels. Further studies are needed to confirm
these results.
ACKNOWLEDGMENTS
The authors wish to thank Wen Jin, MD, for his help in developing the search strate-
gy. The authors have indicated that they have no conflicts of interest regarding the con-
tent of this article.
Dr. Li wrote the initial version of the protocol and commented on drafts of the
review. Dr. Xue performed the primary literature search, initial assessment of trials
and quality analysis, data collection and analysis, and wrote the initial draft of the
review. Dr. Wang checked the literature search, reviewed quality analysis and data
collection, checked and revised the initial draft of the review, and provided clinical
input for the review.
REFERENCES
1. Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility. 5th ed. Balti-
more, Md: Williams & Wilkins; 1994:67.
2. Hornstein MD, Schust D, BerekJS, et al. Infertility. In: BerekJS, Adashi EY, Hillard PA, eds.
NlJVak's Gynecology. 12rh ed. Baltimore, Md: Williams & Wilkins; 1996:935-940.
3. National Collaborating Centre for Women's and Children's Health, National Institute for
Clinical Excellence. Fertility: Assessment and treatment for people with fertility problems.
RCOG Press. 2004. htrp:llwww.rcog.org.uk/files/rcog-corp/uploaded-files/NEBFertilityFull.pdf.
Accessed July 15,2010.
4. Leung AKC, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician. 2004;
70:543-550.
5. Cun YG. Occult hyperprolacrinemia and infertility. Foreign Obstet Gynecol. 2002;29:2.
6. Sauder SE, Frager M, Case GD, er al. Abnormal patterns of pulsatile luteinizing hormone secre-
tion in women with hyperprolactinaernia and amenorrhea: Responses to bromocriprine.] Clin
Endocrinol Metab. 1984;59:941-948.
7. Brown J, Farquhar C, Beck J. Clomiphene and ami-oestrogens for ovulation induction in
PCOS. Cochrane Database Syst Rev. 2009;(4):CD002249.
8. Kousra E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation.
Hum Reprod Update. 1997;3:359-365.
9. Eftekhari N. Fertility rate with bromocriptine in infertile women with galactorrhea and normal
prolactin level.Int Congr Ser. 2004;1271:22-25.
10. Franks S. Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.
Drugs. 1979;17:337-348.
11. Seibel MM, Oskowitz S, Kamrava M, Taymor ML. Bromocriptine response in normopro-
lactinernic patients with polycystic ovary disease: A preliminary report. Obstet Gynecol. 1984;
64:213-219.
12. Padilla SL, Person GK, McDonough PG, Reindollar RH. The efficacy of bromocriptine in
patients with ovulatory dysfunction and normoprolactinemic galactorrhea. Ferti! Steri!.
1985;44:695- 698.
209
CURRENT THERAPEUTIC RESEARCH
13. Asukai K, Uernura T, Minaguchi H. Occult hyperprolaccinemia in infertile women . Fertil
Steril. 1993,60:423--427.
14. J ansen R. Overcoming Infertility: A Compassionate Resource for Getting Pregnant. New York, NY;
W.H. Freeman and Company; 1997.
15. Hu ghes E, Collins J , Vandekerckhove P. Clomiphene cit rate for ovulation induction in women
with oligo-amenorrhoea. Cochrane DatabaseSyst Rev. 2000;(2):CD000056.
16. J adad AR, Moore RA, Carroll D, et at. Assessing the quality of reports of random ised clinical
trials: Is blinding necessary? ControlClin Trials. 1996 ;17:1-12.
17. Moher D, Pham B, Jones A, er at. Does quality of reports of random ised tr ials affect estimates
of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-613.
18. Higgins JP, Green S, eds. CochraneHandbook forSystematic Reviews of Interventions. Version 5.0.0
{updated February 2008}. Th e Cochrane Collaboration; 2008. http://www.cochrane-handbook.
org. Accessed July 15, 2010.
19. Moher D, Cook DJ, Eastwood S, et at. Improving the quality of reports of meta-analyses of
randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses.
Lancet. 1999;354:1896-1900.
20. DeVane GW, Guzick DS. Bromocriptine therapy in normop rolactinemic women with un-
explained infert ility and galactorrhea. Fertil Steril. 1986;46:1026-1031.
21. Parsanezhad ME, Alborzi S, Namavar Jahromi B. A prospect ive, double-blind, randomized ,
placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic
ovary syndrome and normal prolactin level. Arch GynecolObstet. 2004;269:125- 129.
22. Akhlaghi F, Hamedi A. Investigation on the effects of bromocriptine and dexamethasone in
polycystic ovarian disease wirh clomiphene citrate resistance. lnt] Gynecol Obst. 2004;3.
23. Anzhen Y, Liang Y Treatment of bromocriptine in the patients with normal prolact in levels
for ovulation induction. Chin Comp Clin. 2006;22:275- 276.
24. Haixia W. Clinical observation of treatm ent in unexplained infertility with bromocriptine.
Shandong Chin Med. 2002;42:19.
25. Egger M, Davey Smith G , Schneider M, Minder C. Bias in meta-analysis detected by a simple,
g raphical test. 8M). 1997;315:629- 634.
26. Zheng MH, Bai JL, Meng MB. Gabexare mesylare in the preventi on of post-endoscopic retro-
grade cholangiopancreatography pancreatitis: A system atic review and meta-analysis update.
Curr TherRes Clin Exp. 2008;69:288-304.
ADDRESS CORRESPONDENCE TO: Li Shang-Wei , MD , Reproductive Medical
Center of West China Second Hospital , Sichuan University, Chengdu, 610041 China.
E-mail : lishangwei_huaxi@yahoo.cn
210
